Literature DB >> 9108645

Measurement of plasma busulfan concentration by high-performance liquid chromatography with ultraviolet detection.

N Rifai1, M Sakamoto, M Lafi, E Guinan.   

Abstract

Busulfan is widely used in bone marrow transplantation. Increased area under the plasma concentration curve has been shown to correlate with venoocclusive disease, which occurs in approximately 20% of these patients. The authors developed a high performance liquid chromatography assay for the determination of plasma busulfan concentration using ultraviolet detection and a single-step derivatization and extraction. The absolute retention times of busulfan and the internal standard were 2.8 and 5.6 min, respectively. The assay possessed linearity up to 200 mumol/l, sensitivity to at least 0.2 mumol/l, average recovery of 101%, and run-to-run precision (n = 34) of < 7%. Furthermore, the assay proved to be free of interference from 59 medications and correlated highly with a validated method employing gas chromatography with electron capture detection (slope = 0.90, intercept = 0.17, r = 0.98, n = 31). The authors conclude that the method described here is ideally suited for the therapeutic monitoring of busulfan.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9108645     DOI: 10.1097/00007691-199704000-00009

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  5 in total

1.  Glutathione transferase-A2 S112T polymorphism predicts survival, transplant-related mortality, busulfan and bilirubin blood levels after allogeneic stem cell transplantation.

Authors:  Francesca Bonifazi; Gianluca Storci; Giuseppe Bandini; Elena Marasco; Elisa Dan; Elena Zani; Fiorenzo Albani; Sara Bertoni; Andrea Bontadini; Sabrina De Carolis; Maria Rosaria Sapienza; Simonetta Rizzi; Maria Rosa Motta; Martina Ferioli; Paolo Garagnani; Michele Cavo; Vilma Mantovani; Massimiliano Bonafè
Journal:  Haematologica       Date:  2013-09-20       Impact factor: 9.941

2.  Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation.

Authors:  Tiago Nava; Nastya Kassir; Mohamed Aziz Rezgui; Chakradhara Rao Satyanarayana Uppugunduri; Patricia Huezo-Diaz Curtis; Michel Duval; Yves Théoret; Liane E Daudt; Catherine Litalien; Marc Ansari; Maja Krajinovic; Henrique Bittencourt
Journal:  Br J Clin Pharmacol       Date:  2018-04-27       Impact factor: 4.335

3.  Glutathione Transferase Gene Variants Influence Busulfan Pharmacokinetics and Outcome After Myeloablative Conditioning.

Authors:  Sara Bremer; Yngvar Fløisand; Lorentz Brinch; Tobias Gedde-Dahl; Stein Bergan
Journal:  Ther Drug Monit       Date:  2015-08       Impact factor: 3.681

4.  Impact of GSTA1 Polymorphisms on Busulfan Oral Clearance in Adult Patients Undergoing Hematopoietic Stem Cell Transplantation.

Authors:  Veronique Michaud; My Tran; Benoit Pronovost; Philippe Bouchard; Sarah Bilodeau; Karine Alain; Barbara Vadnais; Martin Franco; François Bélanger; Jacques Turgeon
Journal:  Pharmaceutics       Date:  2019-09-01       Impact factor: 6.321

5.  Pharmacokinetics-adapted Busulfan-based myeloablative conditioning before unrelated umbilical cord blood transplantation for myeloid malignancies in children.

Authors:  Joy Benadiba; Marc Ansari; Maja Krajinovic; Marie-France Vachon; Michel Duval; Pierre Teira; Sonia Cellot; Henrique Bittencourt
Journal:  PLoS One       Date:  2018-04-02       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.